Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Sorin Group Signs Supply Agreement for Boston Scientific Lotus(TM) Valve System



  Sorin Group Signs Supply Agreement for Boston Scientific Lotus(TM) Valve
  System

Sorin’s Vancouver site will manufacture transcatheter aortic valve replacement
                                  components

Business Wire

MILAN -- July 15, 2013

Sorin Group (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company
and a leader in the treatment of cardiovascular diseases, announced today the
signing of a supply agreement for the manufacturing of certain components of
the Lotus^TM Aortic Valve System, Boston Scientific Corporation’s
second-generation TAVR (Transcatheter Aortic Valve Replacement) technology.
Under the terms of this agreement, Sorin Group will perform certain
manufacturing steps related to the tissue valve in its facility in Vancouver
(Canada).

“This agreement recognizes the strong valve manufacturing experience that
Sorin Group has accumulated across its European and North American
operations,” said Michel Darnaud, President of Sorin Group, Cardiac Surgery
Business Unit, “building on more than 40 years of innovation, development,
clinical validation and commercialization in the field of mechanical and
tissue prosthetic heart valves.”

The Lotus^TM Aortic Valve System is an investigational device worldwide,
limited by applicable law to investigational use and not available for sale.

About Sorin Group

Sorin Group (www.sorin.com), is a global medical device company and a leader
in the treatment of cardiovascular diseases. The Company develops,
manufactures and markets medical technologies for cardiac surgery and for the
treatment of cardiac rhythm disorders. With 3,750 employees worldwide, the
Company focuses on two major therapeutic areas: Cardiac Surgery
(cardiopulmonary products for open heart surgery and heart valve repair or
replacement products) and Cardiac Rhythm Management (pacemakers,
defibrillators, cardiac resynchronization devices). Every year, over one
million patients are treated with Sorin Group devices in more than 80
countries.

For more information, please visit: www.sorin.com

Contact:

Martine Konorski, Tel: +33 (0)1 46 01 33 78
Director, Corporate Communications
Sorin Group
Mobile: +33 (0)6 76 12 67 73
e-mail: martine.konorski@sorin.com
or
Francesca Rambaudi, Tel: +39 02 69969716
Director, Investor Relations
Sorin Group
e-mail: investor.relations@sorin.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement